Dossier assessment
Solriamfetol (obstructive sleep apnoea) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Solriamfetol (obstructive sleep apnoea) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Solriamfetol (obstructive sleep apnoea) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Improvement of wakefulness and reduction of excessive daytime sleepiness in adult patients with obstructive sleep apnoea (OSA) whose excessive daytime sleepiness has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP)
Added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2022-03-18 A G-BA decision was published.
Project details
- Project no.
- A21-129
- Commission
- Commission awarded on 05.10.2021 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2022-01-03.
Connected Projects
-
Addendum
Solriamfetol (obstructive sleep apnoea) - Addendum to Commission A21-129
Status: Commission completed